JP2010530744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530744A5 JP2010530744A5 JP2010512182A JP2010512182A JP2010530744A5 JP 2010530744 A5 JP2010530744 A5 JP 2010530744A5 JP 2010512182 A JP2010512182 A JP 2010512182A JP 2010512182 A JP2010512182 A JP 2010512182A JP 2010530744 A5 JP2010530744 A5 JP 2010530744A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- seq
- humanized antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 123
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 21
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 21
- 241000288906 Primates Species 0.000 claims description 16
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 12
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 12
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 10
- 206010002022 amyloidosis Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 208000018282 ACys amyloidosis Diseases 0.000 claims description 4
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 4
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 4
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 4
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229940088623 biologically active substance Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000007087 memory ability Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 102000013498 tau Proteins Human genes 0.000 claims description 4
- 108010026424 tau Proteins Proteins 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims description 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000003941 amyloidogenesis Effects 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- DKGJFKPIUSHDIT-UHFFFAOYSA-L disodium;propane-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCS([O-])(=O)=O DKGJFKPIUSHDIT-UHFFFAOYSA-L 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 229960003980 galantamine Drugs 0.000 claims description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004633 pirenzepine Drugs 0.000 claims description 2
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 229960001685 tacrine Drugs 0.000 claims description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 2
- -1 Β-sheet breakers Substances 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 239000005667 attractant Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 13
- 239000000178 monomer Substances 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 7
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94350907P | 2007-06-12 | 2007-06-12 | |
| PCT/US2008/007318 WO2008156622A1 (en) | 2007-06-12 | 2008-06-12 | Humanized antibodies to amyloid beta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046116A Division JP5898715B2 (ja) | 2007-06-12 | 2014-03-10 | アミロイドβに対するヒト化抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530744A JP2010530744A (ja) | 2010-09-16 |
| JP2010530744A5 true JP2010530744A5 (enExample) | 2012-08-30 |
Family
ID=39927964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512182A Withdrawn JP2010530744A (ja) | 2007-06-12 | 2008-06-12 | アミロイドβに対するヒト化抗体 |
| JP2014046116A Active JP5898715B2 (ja) | 2007-06-12 | 2014-03-10 | アミロイドβに対するヒト化抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046116A Active JP5898715B2 (ja) | 2007-06-12 | 2014-03-10 | アミロイドβに対するヒト化抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20090155249A1 (enExample) |
| EP (2) | EP2574345A1 (enExample) |
| JP (2) | JP2010530744A (enExample) |
| KR (2) | KR101670088B1 (enExample) |
| CN (2) | CN104761641A (enExample) |
| AU (2) | AU2008267038B2 (enExample) |
| BR (1) | BRPI0812478A2 (enExample) |
| CA (1) | CA2690435C (enExample) |
| CL (1) | CL2008001741A1 (enExample) |
| CY (1) | CY1115906T1 (enExample) |
| DK (1) | DK2170389T3 (enExample) |
| ES (1) | ES2529174T3 (enExample) |
| HR (1) | HRP20150086T1 (enExample) |
| IL (1) | IL202567B (enExample) |
| MX (1) | MX2009013505A (enExample) |
| NZ (2) | NZ599497A (enExample) |
| PE (2) | PE20090766A1 (enExample) |
| PH (1) | PH12015500507A1 (enExample) |
| PL (1) | PL2170389T3 (enExample) |
| PT (1) | PT2170389E (enExample) |
| RS (1) | RS53793B1 (enExample) |
| RU (1) | RU2567151C2 (enExample) |
| SG (1) | SG182192A1 (enExample) |
| SI (1) | SI2170389T1 (enExample) |
| TW (2) | TW201518320A (enExample) |
| WO (1) | WO2008156622A1 (enExample) |
| ZA (2) | ZA200908870B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| BRPI0818621A8 (pt) * | 2007-10-05 | 2018-01-30 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo |
| US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
| JP5616230B2 (ja) | 2007-11-16 | 2014-10-29 | ザ ロックフェラー ユニバーシティー | ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体 |
| WO2010129276A2 (en) | 2009-04-27 | 2010-11-11 | Case Western Reserve University | PYRO-GLUTAMATE Aβ TARGETING AGENTS |
| WO2010128087A2 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| CN102051407B (zh) * | 2009-11-09 | 2012-12-12 | 中国医学科学院医药生物技术研究所 | Hiv-1前体蛋白早成熟化诱导剂的筛选方法 |
| CN102933604B (zh) | 2010-02-23 | 2016-04-06 | 赛诺菲 | 抗-α2整联蛋白抗体及其用途 |
| CA2788275A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| CN102060911B (zh) * | 2010-11-19 | 2012-11-14 | 清华大学 | 同时结合多种淀粉样蛋白单体的多肽及其应用 |
| PE20140981A1 (es) | 2010-11-30 | 2014-08-20 | Genentech Inc | Anticuerpo para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
| CN102229651A (zh) * | 2011-06-08 | 2011-11-02 | 中南大学 | 一种治疗阿尔茨海默病的淀粉样蛋白膜内片段及其应用 |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| CN102516360B (zh) * | 2011-12-08 | 2013-11-06 | 清华大学 | 一种抑制β分泌酶酶切作用的多肽及其应用 |
| CN120441698A (zh) * | 2012-03-28 | 2025-08-08 | 赛诺菲 | 缓激肽b1受体配体的抗体 |
| JP6419068B2 (ja) | 2012-05-21 | 2018-11-07 | ジェネンテック， インコーポレイテッド | 血液脳関門輸送の安全性を改善するための方法 |
| CN105358578B (zh) | 2013-05-20 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 运铁蛋白受体的抗体及其使用方法 |
| KR102260855B1 (ko) | 2013-09-13 | 2021-06-04 | 제넨테크, 인크. | 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법 |
| NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| JP6628786B2 (ja) * | 2014-07-10 | 2020-01-15 | バイオアークティック アーベー | 改善されたＡβプロトフィブリル結合抗体 |
| CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
| CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP7448174B2 (ja) | 2015-11-09 | 2024-03-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体 |
| JP7065516B2 (ja) | 2015-11-09 | 2022-05-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのｎ末端エピトープおよびそれに対する立体配座選択的抗体 |
| WO2017079835A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CN106749658B (zh) * | 2016-12-15 | 2019-11-12 | 北京师范大学 | 抑制Tau蛋白聚集的抗体型分子伴侣 |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| CA3077418A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized c1q complex |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| JP7748876B2 (ja) | 2019-04-05 | 2025-10-03 | タウク３ バイオロジクス リミテッド | 抗タウｃ３抗体及びその使用 |
| US20230107034A1 (en) * | 2019-07-16 | 2023-04-06 | The Brigham And Women's Hospital, Inc. | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| CN113249335B (zh) * | 2021-06-10 | 2021-10-01 | 南京立顶医疗科技有限公司 | 分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用 |
| CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
| WO2025044931A1 (zh) * | 2023-08-25 | 2025-03-06 | 康诺亚生物医药科技（成都）有限公司 | 阿尔茨海默病治疗剂的开发和应用 |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
| IT1217123B (it) * | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5196412A (en) | 1991-03-06 | 1993-03-23 | Johnson Matthey, Inc. | Gallium compounds |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2123211C (en) * | 1991-11-12 | 2008-09-16 | Colin L. Masters | A method for assaying and treating alzheimer's disease |
| US5880268A (en) * | 1992-01-27 | 1999-03-09 | Icos Corporation | Modulators of the interaction between ICAM-R and αd /CD18 |
| US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5605811A (en) * | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
| EP1308461A3 (en) * | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
| EP0729976A1 (en) * | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| US5626332A (en) * | 1994-07-29 | 1997-05-06 | Harris Corporation | Vibration isolation system using plural signals for control |
| US7129337B1 (en) | 1994-10-21 | 2006-10-31 | Innogenetics N.V. | Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| WO1996036361A1 (en) * | 1995-05-18 | 1996-11-21 | The Regents Of The University Of Michigan | Dna binding antibodies |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| IT1293511B1 (it) * | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| DE69920897T2 (de) * | 1998-04-28 | 2005-10-13 | Smithkline Beecham Corp. | Monoklonale antikörper mit verringerter immunisierungsfähigkeit |
| CN1763097B (zh) * | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6998124B1 (en) * | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
| DE60040024D1 (de) * | 1999-06-16 | 2008-10-02 | Boston Biomedical Res Inst | Immunologische kontrolle des beta-amyloid gehaltes in vivo |
| US20040013647A1 (en) * | 1999-09-03 | 2004-01-22 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating a plaque-forming disease |
| SK288723B6 (sk) * | 2000-02-24 | 2020-01-07 | Univ Washington | Farmaceutický prostriedok a použitie tohto farmaceutického prostriedku |
| US7371365B2 (en) * | 2000-04-04 | 2008-05-13 | Mayo Foundation For Medical Education And Research | Methods for detecting parenchymal plaques in vivo |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP2305822A3 (en) * | 2000-09-06 | 2013-11-06 | Aventis Pharma S.A. | Methods and compositions for diseases associated with Amyloidosis |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| EP1385545B1 (en) * | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
| DE60229051D1 (de) * | 2001-04-30 | 2008-11-06 | Lilly Co Eli | Humanisierte antikörper |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1270592B1 (de) * | 2001-06-12 | 2004-09-29 | Wiltfang, Jens | Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa |
| US6638722B2 (en) * | 2001-06-13 | 2003-10-28 | Invitrogen Corporation | Method for rapid amplification of DNA |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| EP1420032B2 (en) * | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
| US20040241164A1 (en) * | 2001-08-17 | 2004-12-02 | Bales Kelly Renee | Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass |
| US7771722B2 (en) * | 2001-08-17 | 2010-08-10 | Eli Lilly And Company | Assay method for alzheimer's disease |
| EP1519740A4 (en) * | 2001-08-17 | 2005-11-09 | Lilly Co Eli | FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA |
| JP2005503789A (ja) * | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Ａβ抗体 |
| CN100488982C (zh) * | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
| EP1975179A1 (en) * | 2001-12-26 | 2008-10-01 | Araclon Biotech, S.L. | Polyclonal antibodies, preparation method thereof and use of same |
| SI1461359T1 (sl) * | 2002-01-18 | 2007-06-30 | Pf Medicament | Nova anti IGF-IR protitelesa in njihova uporaba |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US20070134247A9 (en) * | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| AU2003223474B2 (en) * | 2002-04-25 | 2008-09-04 | Eli Lilly And Company | Method for treating anxiety and mood disorders in older subjects |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
| AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| EP1439192A1 (en) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Neuropilin-1 inhibitors |
| WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AU2004204494B2 (en) * | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AT413945B (de) * | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) * | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| EP1613657A2 (en) * | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| EP1469312A1 (en) * | 2003-04-18 | 2004-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis of Alzheimer's disease |
| TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| US20050124016A1 (en) * | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| WO2005025616A1 (ja) * | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| EP1660533A4 (en) * | 2003-09-12 | 2009-10-21 | Univ California | MONOCLONAL ANTIBODIES SPECIFIC TO HIGH MOLECULAR WEIGHT AGGREGATION INTERMEDIATES COMMON TO AMYLOIDS FORMED FROM PROTEINS OF DIFFERENT SEQUENCE |
| US20070015218A1 (en) * | 2003-10-14 | 2007-01-18 | University Of South Florida | A Method for the Separation Anti-Amyloid Beta Antibody with Amyloid Beta Peptide |
| US7807157B2 (en) * | 2004-02-20 | 2010-10-05 | Intellect Neurosciences Inc. | Monoclonal antibodies and use thereof |
| WO2005105998A1 (ja) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0513959A (pt) * | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| WO2006040153A2 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AR051800A1 (es) * | 2004-12-15 | 2007-02-07 | Wyeth Corp | Anticuerpos a beta usados en mejorar la cognicion |
| WO2006069081A2 (en) * | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| KR20080021585A (ko) * | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| ES2259270B1 (es) * | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| US7825223B2 (en) * | 2005-06-17 | 2010-11-02 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A β antibodies |
| RU2008120027A (ru) * | 2005-10-21 | 2009-11-27 | Мерк энд Ко., Инк. (US) | Анти-addl моноклональное антитело и его применение |
| KR101667623B1 (ko) * | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| MY167887A (en) * | 2005-12-12 | 2018-09-26 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| DK2074145T5 (en) * | 2006-10-02 | 2017-10-16 | Ac Immune Sa | HUMANIZED ANTIBODY AGAINST AMYLOID BETA |
| JP2008135645A (ja) * | 2006-11-29 | 2008-06-12 | Toshiba Corp | 多層プリント配線板および多層プリント配線板の層間接合方法 |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| CN103179981B (zh) * | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
-
2008
- 2008-06-12 ES ES08768371.0T patent/ES2529174T3/es active Active
- 2008-06-12 PE PE2008001010A patent/PE20090766A1/es not_active Application Discontinuation
- 2008-06-12 DK DK08768371.0T patent/DK2170389T3/en active
- 2008-06-12 SI SI200831359T patent/SI2170389T1/sl unknown
- 2008-06-12 WO PCT/US2008/007318 patent/WO2008156622A1/en not_active Ceased
- 2008-06-12 TW TW103125879A patent/TW201518320A/zh unknown
- 2008-06-12 CN CN201510162275.XA patent/CN104761641A/zh active Pending
- 2008-06-12 CA CA2690435A patent/CA2690435C/en active Active
- 2008-06-12 PE PE2013000113A patent/PE20131334A1/es active IP Right Grant
- 2008-06-12 CN CN200880103155.0A patent/CN101820911B/zh active Active
- 2008-06-12 RS RS20150045A patent/RS53793B1/sr unknown
- 2008-06-12 PL PL08768371T patent/PL2170389T3/pl unknown
- 2008-06-12 KR KR1020107000719A patent/KR101670088B1/ko active Active
- 2008-06-12 US US12/138,372 patent/US20090155249A1/en not_active Abandoned
- 2008-06-12 KR KR1020157011525A patent/KR20150055103A/ko not_active Ceased
- 2008-06-12 AU AU2008267038A patent/AU2008267038B2/en active Active
- 2008-06-12 RU RU2010100342/10A patent/RU2567151C2/ru active
- 2008-06-12 JP JP2010512182A patent/JP2010530744A/ja not_active Withdrawn
- 2008-06-12 SG SG2012043279A patent/SG182192A1/en unknown
- 2008-06-12 CL CL2008001741A patent/CL2008001741A1/es unknown
- 2008-06-12 BR BRPI0812478A patent/BRPI0812478A2/pt not_active Application Discontinuation
- 2008-06-12 EP EP20120173871 patent/EP2574345A1/en not_active Withdrawn
- 2008-06-12 NZ NZ599497A patent/NZ599497A/xx unknown
- 2008-06-12 NZ NZ581834A patent/NZ581834A/en unknown
- 2008-06-12 PT PT87683710T patent/PT2170389E/pt unknown
- 2008-06-12 MX MX2009013505A patent/MX2009013505A/es active IP Right Grant
- 2008-06-12 TW TW097121924A patent/TWI557136B/zh active
- 2008-06-12 HR HRP20150086AT patent/HRP20150086T1/hr unknown
- 2008-06-12 EP EP08768371.0A patent/EP2170389B1/en active Active
-
2009
- 2009-12-07 IL IL202567A patent/IL202567B/en active IP Right Grant
- 2009-12-11 ZA ZA2009/08870A patent/ZA200908870B/en unknown
-
2011
- 2011-04-07 ZA ZA2011/02599A patent/ZA201102599B/en unknown
-
2014
- 2014-03-10 JP JP2014046116A patent/JP5898715B2/ja active Active
- 2014-07-16 AU AU2014204465A patent/AU2014204465B2/en active Active
-
2015
- 2015-01-16 CY CY20151100048T patent/CY1115906T1/el unknown
- 2015-03-09 PH PH12015500507A patent/PH12015500507A1/en unknown
- 2015-07-20 US US14/803,224 patent/US20160168234A1/en not_active Abandoned
-
2018
- 2018-02-22 US US15/903,007 patent/US20190031746A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530744A5 (enExample) | ||
| JP2010505415A5 (enExample) | ||
| RU2010100342A (ru) | Гуманизированные антитела к амилоиду бета | |
| RU2009104769A (ru) | Гуманизированное антитело к амилоиду бета | |
| KR101783058B1 (ko) | 원시섬유 형태의 베타-아밀로이드 펩티드에 대해 특이적인 인간화 항체 | |
| KR101781228B1 (ko) | 인간 항-알파-시누클레인 자가항체 | |
| CN103796679B (zh) | 抗-α突触核蛋白结合分子 | |
| JP2010530227A5 (enExample) | ||
| KR102680924B1 (ko) | 인간 항-세마포린 4d 항체 | |
| CN111471106A (zh) | 人源抗转甲状腺素蛋白抗体、多核苷酸、载体及其应用 | |
| CN104144700B (zh) | 抗CD1d的抗体 | |
| TW200840821A (en) | Methods of purifying anti A beta antibodies | |
| CN114341181B (zh) | 抗ms4a4a抗体及其使用方法 | |
| CN115298214A (zh) | 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白 | |
| WO2023163187A1 (ja) | 神経変性疾患の治療剤 | |
| CN106573972A (zh) | 交联B淋巴细胞的CD23但不致敏肥大细胞的人源化抗‑IgE抗体 | |
| CN116348487A (zh) | 抗淀粉样β抗体 | |
| RU2013115283A (ru) | Гуманизированное антитело к амилоиду бета | |
| AU2003289998B2 (en) | Antibody ("11C7") anti Nogo A and its pharmaceutical use | |
| EP3655431A1 (en) | ANTI- ISOASP7 AMYLOID beta (Abeta) ANTIBODIES AND USES THEREOF | |
| HK40113703A (zh) | 神经变性疾病的治疗剂 | |
| JP2010528583A5 (enExample) | ||
| WO2025047850A1 (ja) | 神経変性疾患の治療剤 | |
| JP2019004892A (ja) | アミロイドβに対するヒト化抗体 | |
| HK1158946B (en) | Diagnostic antibody assay |